查詢結果分析
來源資料
相關文獻
- 人類癌症基因體以驗證探討抗癌中草藥- 子計畫六、中草藥調節抑癌基因對抗肝癌機制的探討
- 人類癌症基因體以驗證探討抗癌中草藥--子計畫六、中草藥調節抑癌基因對抗肝癌機制的探討
- 人類癌症基因體以驗證探討抗癌中草藥--子計畫六、中草藥調節抑癌基因對抗肝癌機制的探討
- 人類癌症基因體以驗證探討抗癌中草藥子計畫一、中草藥調節生長因子及其接受器基因對抗肝癌機制的探討(2-1)
- 人類癌症基因體以驗證探討抗癌中草藥子計畫二、中草藥調節生長因子及其接受器基因對抗肝癌機制的探討(2-2)
- 人類癌症基因體以驗證探討抗癌中草藥--總計畫
- 人類癌症基因體以驗證探討抗癌中草藥--總計畫
- 自由基,免疫反應與病因:脂肪肝、肝硬化和肝癌
- 肝病中醫之診治
- 生物科技對於開發中草藥的應用與發展策略
頁籤選單縮合
題名 | 人類癌症基因體以驗證探討抗癌中草藥- 子計畫六、中草藥調節抑癌基因對抗肝癌機制的探討=Evidenced-base Studies on Anticancer of Chinese Herbs by Genomic Medicine- subproject 6-Studies on the Anticancer Activity of Chinese Herbs: Regulation of Apoptosis Related Genes and Tumor Suppressor-related Genes |
---|---|
作 者 | 呂紹俊; | 書刊名 | 中醫藥年報 |
卷期 | 28:7 2010.09[民99.09] |
頁次 | 頁341-360 |
分類號 | 414.32 |
關鍵詞 | 肝癌; 中草藥; 基因體; 脂肪肝; Hepatocarcinoma; Chinese herbs; Genomic; Fatty liver; |
語文 | 中文(Chinese) |
中文摘要 | 以基因體學方法尋找可用於抗肝癌之作用及能降低肝臟脂肪之中草藥。 第二年將細胞層次以肝癌細胞株分析第一年篩選出有效果的中草藥萃取液對 癌細胞的影響,如細胞群落形成 (colony forming)、細胞移動(migration),細胞增生,凋亡及細胞週期等的影響,由細胞層次驗證中草藥萃取液的抗癌功能。 將NF- B-Luciferase、AP1-Luciferase報導基因轉染到肝癌細胞,篩選能 抑制AP1-Luciferase、NF- B-Luciferase之中草藥萃取液,進一步用反轉錄-即 時定量聚合酵素鏈鎖反應(RT-qPCR)定量與癌症相關基因的表現變化。測量中草藥萃取液對肝細胞三酸甘油酯影響。 測試了18種方劑及17種單方藥材發現有3種方劑及12種單方藥材對NF- B promoter所drive的Luciferase表現有抑制作用;所有藥材對AP-1 promoter所 drive的Luciferase表現都沒有抑制作用。有4種方劑及9種單方藥材可以降低肝細胞TG。小柴胡湯中的黃芩在10-15mg/ml劑量下具毒殺肝癌細胞的作用,可 抑制CCND1、ERBB2、CDC2等基因的mRNA及蛋白質表現量;影響細胞週 期,使S phase下降,G2/M上升。 |
英文摘要 | To screen Chinese medicines that could inhibit activation of AP1 and NF-κB by Luciferase reporter assay systems. Furthermore, the expression of endogenous genes that controlled by AP1 and NF-κB is evaluated by qRT-PCR and Western blot analyses. In the future year, the effects of these Chinese medicines on cancer cell will be investigated by colony forming, cell migration, cell proliferation and apoptosis methods. Moreover, the Chinese medicines that can potentially ameliorate fatty liver were screened. The NF-κB-Luciferase、AP1-Luciferase reporter plasmids were transfected into HepG2 cells and treated with various of Chinese medicines extracts. The activity of luciferases were assayed 24 h after treatment. The mRNA expression of 42 cancer related genes were determined by RT-qPCR assays. The contents of cellular triacylglycerol (TG) were determined by enzymatic assay 48 h after treatment. Total of 35 Chinese medicines were screened, 15 of them could decrease luciferase activity that was driven by NF-κB promoter. None of them could decrease luciferase activity that was driven by Ap-1 promoter. We identified 13 Chinese medicines that could decrease the content of cellular TG. Huang-Qin in the dose of 10-15mg/ml could kill HepG2 cells, it decrease the expression of CCND1、ERBB2、CDC2 mRNA and protein in a dose dependent manner. Furthermore, treatment with Huang-Qin resulted in decrease of cells in S phase and increase G2/ M cells. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。